

# Mariano Provencio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1942335/publications.pdf>

Version: 2024-02-01

333  
papers

17,833  
citations

29994

54  
h-index

14702

127  
g-index

344  
all docs

344  
docs citations

344  
times ranked

19606  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 711-728.	1.8	12
2	Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. BMC Cancer, 2022, 22, .	1.1	6
3	Effect of intravenous lidocaine on ischemia-reperfusion injury in DIEP microsurgical breast reconstruction. A prospective double-blind randomized controlled clinical trial. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, 74, 809-818.	0.5	2
4	Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Molecular Oncology, 2021, 15, 43-56.	2.1	18
5	Overall survival for early and locally advanced non-small-cell lung cancer from one institution: 2000-2017. Clinical and Translational Oncology, 2021, 23, 1325-1333.	1.2	7
6	Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cancer, 2021, 21, 230.	1.1	9
7	Residential radon and lung cancer characteristics at diagnosis. International Journal of Radiation Biology, 2021, 97, 997-1002.	1.0	4
8	Small-cell lung cancer in never-smokers. ESMO Open, 2021, 6, 100059.	2.0	19
9	Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. European Journal of Cancer, 2021, 149, 61-72.	1.3	21
10	Cancer and SARS-CoV-2 Infection: A Third-Level Hospital Experience. Clinical Epidemiology, 2021, Volume 13, 317-324.	1.5	5
11	Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. PLoS ONE, 2021, 16, e0251761.	1.1	17
12	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Management, 2021, 10, LMT51.	1.5	10
13	Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 2021, 22, 86.	1.3	10
14	R-Score: A New Parameter to Assess the Quality of Variants™ Calls Assessed by NGS Using Liquid Biopsies. Biology, 2021, 10, 954.	1.3	1
15	Are there differences by sex in lung cancer characteristics at diagnosis? a nationwide study. Translational Lung Cancer Research, 2021, 10, 3902-3911.	1.3	8
16	KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. ESMO Open, 2021, 6, 100279.	2.0	6
17	Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. Clinical and Translational Oncology, 2020, 22, 21-36.	1.2	39
18	Next-generation sequencing for tumor mutation quantification using liquid biopsies. Clinical Chemistry and Laboratory Medicine, 2020, 58, 306-313.	1.4	10

#	ARTICLE	IF	CITATIONS
19	ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib. <i>Translational Lung Cancer Research</i> , 2020, 9, 532-540.	1.3	17
20	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. <i>Cancers</i> , 2020, 12, 3459.	1.7	11
21	Lung cancer symptoms at diagnosis: results of a nationwide registry study. <i>ESMO Open</i> , 2020, 5, e001021.	2.0	15
22	Lung cancer risk and residential radon exposure: A pooling of case-control studies in northwestern Spain. <i>Environmental Research</i> , 2020, 189, 109968.	3.7	38
23	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1413-1422.	5.1	475
24	Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 366-372.	1.3	19
25	Reconstructing the patient's natural history from electronic health records. <i>Artificial Intelligence in Medicine</i> , 2020, 105, 101860.	3.8	14
26	Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. <i>JCO Oncology Practice</i> , 2020, 16, e298-e305.	1.4	6
27	Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. <i>Lung Cancer</i> , 2020, 147, 83-90.	0.9	12
28	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	0.5	34
29	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	0.5	205
30	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 245-255.	1.2	41
31	Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model. <i>Scientific Reports</i> , 2020, 10, 7078.	1.6	17
32	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. <i>JAMA Oncology</i> , 2020, 6, 1063.	3.4	70
33	Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. <i>Cancer Epidemiology</i> , 2020, 67, 101737.	0.8	15
34	Abstract 929: Transcriptomic analysis of pre-treatment tissue samples to predict clinical benefit to durvalumab in HIV-infected cancer patients. , 2020, , .		0
35	Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma. <i>Exercise Immunology Review</i> , 2020, 26, 100-115.	0.4	10
36	Recognition of Time Expressions in Spanish Electronic Health Records. , 2019, , .		10

#	ARTICLE	IF	CITATIONS
37	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3003-3014.	1.1	42
38	Residential radon, genetic polymorphisms in DNA damage and repair-related. <i>Lung Cancer</i> , 2019, 135, 10-15.	0.9	21
39	Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients. <i>Annals of Oncology</i> , 2019, 30, v507.	0.6	2
40	Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2019, 30, v594.	0.6	0
41	Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS). <i>Annals of Oncology</i> , 2019, 30, v624.	0.6	2
42	SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 389-390.	0.8	0
43	Comparison of variant calling algorithms in NGS analysis. <i>Clinica Chimica Acta</i> , 2019, 493, S113-S114.	0.5	0
44	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). <i>Translational Lung Cancer Research</i> , 2019, 8, 461-475.	1.3	38
45	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.	2.0	38
46	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	0.9	24
47	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	0.5	78
48	Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2019, 35, 1761-1767.	0.9	1
49	Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. <i>European Journal of Cancer</i> , 2019, 116, 137-147.	1.3	167
50	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1997-2007.	0.8	170
51	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
52	Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 1464-1471.	1.2	1
53	Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1 $\beta$ in NSCLC which can be overcome by OXPHOS inhibition. <i>Free Radical Biology and Medicine</i> , 2019, 135, 167-181.	1.3	108
54	Lung cancer and residential radon in never-smokers: A pooling study in the Northwest of Spain. <i>Environmental Research</i> , 2019, 172, 713-718.	3.7	60

#	ARTICLE	IF	CITATIONS
55	Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group. <i>Hematological Oncology</i> , 2019, 37, 143-150.	0.8	9
56	Applying Data Science methods and tools to unveil healthcare use of lung cancer patients in a teaching hospital in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1472-1481.	1.2	1
57	Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 34.	2.8	23
58	Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma. <i>Immunotherapy</i> , 2019, 11, 379-384.	1.0	7
59	Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , 2019, 14, e0212813.	1.1	31
60	How we treat patients with lung cancer during the SARS-CoV-2 pandemic. <i>ESMO Open</i> , 2019, 4, e000785.	2.0	2
61	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102.	1.9	37
62	EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. <i>Hematological Oncology</i> , 2019, 37, 387-389.	0.8	6
63	P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2019, 14, S711.	0.5	6
64	Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 4092-4095.	0.6	5
65	EP1.14-11 Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2019, 14, S1036.	0.5	0
66	P2.16-34 Is Prophylactic Cranial Irradiation Useful in Real World?. <i>Journal of Thoracic Oncology</i> , 2019, 14, S878-S879.	0.5	0
67	MA02.01 Recurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial). <i>Journal of Thoracic Oncology</i> , 2019, 14, S252.	0.5	0
68	MA08.11 SLCC SCAT Trial: Surgical Audit to Lymph Node Assessment Based on IASLC Recommendations. <i>Journal of Thoracic Oncology</i> , 2019, 14, S281.	0.5	0
69	MA22.05 Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S340.	0.5	0
70	P2.03-33 ctDNA Levels Significantly Predicts Survival in NSCLC Patients with an EGFR Activating Mutation. <i>Journal of Thoracic Oncology</i> , 2019, 14, S696.	0.5	2
71	P2.16-20 Big Data and Survival Predictors in Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2019, 14, S873.	0.5	0
72	MA16.03 Big Data Analysis for Personalized Medicine in Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2019, 14, S313-S314.	0.5	0

#	ARTICLE	IF	CITATIONS
73	P1.03-15 Non-Invasive Detection of Secondary Resistance Mutations in ALK-Positive NSCLC Patients by Next-Generation Sequencing. <i>Journal of Thoracic Oncology</i> , 2019, 14, S423.	0.5	1
74	P2.03-16 Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing. <i>Journal of Thoracic Oncology</i> , 2019, 14, S688-S689.	0.5	0
75	P2.10-05 Indoor Radon and Lung Cancer Risk. A Pooling Study on the Second Risk Factor for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, S786.	0.5	1
76	P1.16-12 An Analysis of Healthcare Use and the Cost Associated to End-of-Life Care of Lung Cancer Patients in a Spanish Hospital. <i>Journal of Thoracic Oncology</i> , 2019, 14, S590-S591.	0.5	0
77	P2.01-12 A Phase I/II Trial of IO102 and Pembrolizumab With/Without Chemotherapy as First-line Treatment of Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, S643.	0.5	0
78	EP1.16-28 ALK Translocated Patients: Survival in an Unselected Population. <i>Journal of Thoracic Oncology</i> , 2019, 14, S1075.	0.5	0
79	P2.10-02 Smoking Habit in Lung Cancer in Spain. <i>Journal of Thoracic Oncology</i> , 2019, 14, S784-S785.	0.5	0
80	ES02.04 Concurrent, Sequential and Combination Immunotherapy Regimens in LA-NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, S17-S18.	0.5	2
81	OA13.05 NADIM Study: Updated Clinical Research and Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, S241.	0.5	31
82	OA09.06 Residential Radon, Smoking and Lung Cancer Risk. A Case-Control Study in a Radon Prone Area. <i>Journal of Thoracic Oncology</i> , 2019, 14, S230.	0.5	0
83	P2.05-10 Liquid Biopsy: Association Between the Burden of Disease in Patients with EGFR-Mutated NSCLC and the Frequency of Its Detection in Blood. <i>Journal of Thoracic Oncology</i> , 2019, 14, S751.	0.5	0
84	P2.05-12 Analysis of Biomarkers in Lung Cancer in Spain. <i>Journal of Thoracic Oncology</i> , 2019, 14, S752.	0.5	0
85	Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years. <i>Leukemia and Lymphoma</i> , 2019, 60, 856-859.	0.6	4
86	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 304-310.	0.5	10
87	Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. <i>Annals of Oncology</i> , 2019, 30, 290-296.	0.6	55
88	Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF- $\beta$ 2 signaling. <i>Free Radical Biology and Medicine</i> , 2019, 130, 163-173.	1.3	91
89	Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies. <i>Pathology Research and Practice</i> , 2019, 215, 392-394.	1.0	11
90	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110

#	ARTICLE	IF	CITATIONS
91	Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study). <i>Lung Cancer</i> , 2019, 135, 161-168.	0.9	10
92	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
93	Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2019, 60, 1576-1579.	0.6	0
94	A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. <i>Clinical and Translational Oncology</i> , 2019, 21, 489-498.	1.2	65
95	Lung cancer in Spanish women: The WORLD07 project. <i>European Journal of Cancer Care</i> , 2019, 28, e12941.	0.7	6
96	Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer. <i>Annals of Oncology</i> , 2019, 30, v750.	0.6	1
97	A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis. <i>Blood</i> , 2019, 134, 4078-4078.	0.6	17
98	Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2501-2501.	0.8	14
99	Lung cancer characteristics in never smokers. Results from the LCRINS study. , 2019, , .		0
100	Alcohol consumption and lung cancer risk in never smokers: a pooled analysis of case-control studies. <i>European Journal of Public Health</i> , 2018, 28, 521-527.	0.1	13
101	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1266-1272.	0.6	106
102	Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. <i>Annals of Oncology</i> , 2018, 29, 439-444.	0.6	14
103	Características al diagnóstico y supervivencia de estadios I y II de cáncer de pulmón. <i>Archivos De Bronconeumología</i> , 2018, 54, 420-426.	0.4	4
104	Lung cancer in lung transplantation: incidence and outcome. <i>Postgraduate Medical Journal</i> , 2018, 94, 15-19.	0.9	22
105	P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, S596.	0.5	0
106	OA05.06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S332.	0.5	4
107	OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S320.	0.5	6
108	ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses. <i>Annals of Oncology</i> , 2018, 29, ix145-ix146.	0.6	1

#	ARTICLE	IF	CITATIONS
109	MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S358-S359.	0.5	1
110	P2.03-15 Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, S721-S722.	0.5	0
111	P1.15-24 Small Cell Lung Cancer: Clinical Characteristics and Survival of a Spanish Cohort of 221 Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, S621-S622.	0.5	0
112	Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients. <i>Oncotarget</i> , 2018, 9, 488-494.	0.8	30
113	P2.15-25 NIVEX TRIAL (GCEP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, S827.	0.5	0
114	Profiling Lung Cancer Patients Using Electronic Health Records. <i>Journal of Medical Systems</i> , 2018, 42, 126.	2.2	17
115	An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement. <i>PLoS ONE</i> , 2018, 13, e0193233.	1.1	9
116	Hyperprogression as a distinct outcome after immunotherapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 16-21.	3.4	89
117	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106.	1.1	9
118	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , 2018, 24, 5543-5551.	3.2	18
119	Abstract A084: DENALI: a 3-arm double-blind randomized phase 2 study of carboplatin, pemetrexed, and placebo (CPP) versus carboplatin, pemetrexed, and either 1 or 2 truncated courses of demcizumab (CPD) in patients with non-squamous non-small cell lung cancer (NSCLC). <i>Molecular Cancer Therapeutics</i> , 2018, 17, A084-A084.	1.9	3
120	Long-term follow up of Hodgkin lymphoma. <i>Oncotarget</i> , 2018, 9, 11638-11645.	0.8	7
121	Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib. <i>Annals of Translational Medicine</i> , 2018, 6, S31-S31.	0.7	0
122	Association of <i>DDX58</i> 177 C>T polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosis classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 438-444.	0.6	2
123	Follicular lymphomas and their transformation: Past and current research. <i>Expert Review of Hematology</i> , 2017, 10, 515-524.	1.0	8
124	Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer. <i>Oncology Letters</i> , 2017, 13, 1647-1654.	0.8	5
125	Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group. <i>Cancer</i> , 2017, 123, 3709-3716.	2.0	23
126	Exercise and the Hallmarks of Cancer. <i>Trends in Cancer</i> , 2017, 3, 423-441.	3.8	124

#	ARTICLE	IF	CITATIONS
127	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.	0.9	18
128	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. <i>Cancer Investigation</i> , 2017, 35, 358-365.	0.6	9
129	Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study. <i>Cancer Letters</i> , 2017, 411, 130-135.	3.2	9
130	Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S326-S327.	0.2	2
131	Cáncer de pulmón microcítico. Metodología y resultados preliminares del estudio SMALL CELL. <i>Archivos De Bronconeumología</i> , 2017, 53, 675-681.	0.4	5
132	Lung cancer as a cardiotoxic state: a review. <i>Medical Oncology</i> , 2017, 34, 159.	1.2	12
133	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	128
134	PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy. <i>Scientific Reports</i> , 2017, 7, 16661.	1.6	21
135	Small Cell Lung Cancer. Methodology and Preliminary Results of the SMALL CELL Study. <i>Archivos De Bronconeumología</i> , 2017, 53, 675-681.	0.4	0
136	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , 2017, 19, 1537-1542.	1.2	4
137	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, 178-188.e4.	1.1	5
138	Spotlight on the relevance of mtDNA in cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 409-418.	1.2	19
139	Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 186-191.	0.2	29
140	OncoCall: Analyzing the Outcomes of the Oncology Telephone Patient Assistance. , 2017, , .		0
141	P3.01-005 ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2202.	0.5	0
142	P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2230.	0.5	0
143	Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK). <i>ADMET and DMPK</i> , 2017, 5, 1.	1.1	0
144	ASTRIS: A multicenter, real world treatment study of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2017, 28, ii49-ii50.	0.6	0

#	ARTICLE	IF	CITATIONS
145	PIK3CA mutation and PDL1 expression in lung squamous cell carcinoma surgically resected. <i>Annals of Oncology</i> , 2017, 28, v600.	0.6	0
146	Mutational profile of primary breast diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 102888-102897.	0.8	22
147	Twice-daily chemoradiotherapy must still be the choice for patients with limited-stage small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2843-2846.	0.6	0
148	Copanlisib in patients with relapsed or refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7535-7535.	0.8	5
149	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9036-9036.	0.8	10
150	Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. <i>PLoS ONE</i> , 2017, 12, e0177204.	1.1	18
151	mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish Lymphoma Oncology Group. <i>Oncotarget</i> , 2017, 8, 50949-50957.	0.8	31
152	Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 59408-59416.	0.8	12
153	Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment. <i>Oncotarget</i> , 2017, 8, 60291-60298.	0.8	22
154	Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets. <i>Oncotarget</i> , 2017, 8, 111386-111395.	0.8	33
155	Noninvasive EGFR testing in plasma circulating free DNA (cfDNA) by a new diagnostic method to detect point mutations, deletions and insertions associated to non small cell lung cancer: <i>CLART CMA EGFR LB</i>.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20008-e20008.	0.8	0
156	Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. <i>Translational Lung Cancer Research</i> , 2016, 5, 455-465.	1.3	79
157	CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3 $\beta$ signaling pathway. <i>Oncotarget</i> , 2016, 7, 68781-68791.	0.8	51
158	Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing. <i>Translational Lung Cancer Research</i> , 2016, 5, 665-672.	1.3	114
159	Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients. Impact on biomarker testing. <i>Annals of Oncology</i> , 2016, 27, vi20.	0.6	0
160	Residential radon, <i>EGFR</i> mutations and <i>ALK</i> alterations in never-smoking lung cancer cases. <i>European Respiratory Journal</i> , 2016, 48, 1462-1470.	3.1	32
161	Cause-specific mortality after follicular non-Hodgkin lymphoma: a report from the Spanish Lymphoma Study Group (GOTEL). <i>Annals of Oncology</i> , 2016, 27, vi315.	0.6	0
162	Survival in young adults diagnosed with follicular lymphoma in a national registry from the Spanish Lymphoma Oncology Group. <i>Annals of Oncology</i> , 2016, 27, vi316.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Survival in young adults diagnosed with follicular lymphoma. <i>Annals of Oncology</i> , 2016, 27, 751.	0.6	2
164	Identification of exosomes in non-Hodgkin B-cell lymphomas. Prognostic usefulness in patients treated with rituximab-chemotherapy: a prospective, multicenter correlation study by the Spanish Lymphoma Oncology Group (GOTEL). <i>Annals of Oncology</i> , 2016, 27, vi318.	0.6	0
165	Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma. <i>Clinical and Translational Oncology</i> , 2016, 18, 99-106.	1.2	10
166	Small cell lung cancer in never-smokers. <i>European Respiratory Journal</i> , 2016, 47, 947-953.	3.1	32
167	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 3502-3502.	0.6	21
168	Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study. <i>Blood</i> , 2016, 128, 623-623.	0.6	7
169	Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3530-3530.	0.8	2
170	Randomized phase II trial (RENO): Efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC)â€”SLCG 10/02.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8538-8538.	0.8	1
171	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. <i>Anticancer Research</i> , 2016, 36, 6647-6654.	0.5	9
172	Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8529-8529.	0.8	0
173	Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkinâ€™s lymphoma (R-R NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7545-7545.	0.8	0
174	Abstract 265: Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising approach to improve the efficacy of EGFR-TKIs in the treatment of NSCLC patients. , 2016, , .		0
175	Is residential radon associated with mutations in drivers genes in never smokers lung cancer cases? The case of EGFR and ALK. , 2016, , .		0
176	3211 Follicular lymphoma and clinical characteristics of histologic transformation. <i>European Journal of Cancer</i> , 2015, 51, S652-S653.	1.3	0
177	3202 Clinical characteristics of primary breast lymphoma. <i>European Journal of Cancer</i> , 2015, 51, S649.	1.3	0
178	Alpha-1 Antitrypsin Deficiency and Lung Cancer Risk. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1279-1284.	0.5	27
179	3074 Platinum-pemetrexed palliative chemotherapy in malignant pleural mesothelioma from Spanish BEMME database The Spanish Lung Cancer Group (SLCG). <i>European Journal of Cancer</i> , 2015, 51, S622.	1.3	0
180	Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. <i>Oncoscience</i> , 2015, 2, 131-141.	0.9	57

#	ARTICLE	IF	CITATIONS
181	HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02. <i>PLoS ONE</i> , 2015, 10, e0135512.	1.1	9
182	Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. <i>Cancer Treatment Reviews</i> , 2015, 41, 680-689.	3.4	43
183	Sentinel lymph node biopsy in breast cancer: the role of micrometastasis. <i>Medical Oncology</i> , 2015, 32, 450.	1.2	1
184	Role of vascular endothelial growth factor C in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1286-1294.	0.6	10
185	A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. <i>Acta Oncologica</i> , 2015, 54, 933-938.	0.8	11
186	Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. <i>Cancer Epidemiology</i> , 2015, 39, 291-297.	0.8	39
187	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 328-337.	5.1	124
188	Residential radon and lung cancer characteristics in never smokers. <i>International Journal of Radiation Biology</i> , 2015, 91, 605-610.	1.0	23
189	Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?. <i>Leukemia and Lymphoma</i> , 2015, 56, 1686-1690.	0.6	5
190	Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 1528-1528.	0.6	7
191	Can curcumin induces selective packaging of miRNAs in exosomes? A pilot study in chronic myelogenous leukemia cells.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13563-e13563.	0.8	1
192	Exosomes enriched in stemness/metastatic-related mRNAs promote oncogenic potential in breast cancer. <i>Oncotarget</i> , 2015, 6, 40575-40587.	0.8	70
193	The role of ALDH1 and CD133 expression as stem cell tumor marker in early-stage NSCLC.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13508-e13508.	0.8	0
194	Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection. <i>Blood</i> , 2015, 126, 3874-3874.	0.6	0
195	Immunohistochemical and Molecular Characteristics with Prognostic Significance in Diffuse Large B-Cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e98169.	1.1	31
196	Lenalidomide Plus Metronomic Cyclophosphamide for Heavily Pretreated Classical Hodgkin Lymphoma. a Phase II Trial. <i>Annals of Oncology</i> , 2014, 25, iv330.	0.6	0
197	Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. <i>Leukemia and Lymphoma</i> , 2014, 55, 51-55.	0.6	21
198	High serum levels of vascular endothelial growth factor-C have a positive impact on outcome of patients with advanced diffuse large B cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 1413-1416.	0.6	5

#	ARTICLE	IF	CITATIONS
199	Different exosome cargo from plasma/bronchoalveolar lavage in non-small cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 713-724.	1.5	121
200	New drugs and targeted treatments in Hodgkin's lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 457-464.	3.4	10
201	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014, 25, 2147-2155.	0.6	27
202	Aldehyde dehydrogenases in early stage lung cancer: nuclear expression. <i>Clinical and Translational Oncology</i> , 2014, 16, 931-934.	1.2	7
203	Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. <i>Haematologica</i> , 2014, 99, e138-e141.	1.7	2
204	PLCG1 mutations in cutaneous T-cell lymphomas. <i>Blood</i> , 2014, 123, 2034-2043.	0.6	193
205	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8051-8051.	0.8	22
206	Therapeutic integration of new molecule-targeted therapies with radiotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 89-94.	1.3	16
207	Thoracic malignancies after Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19520-e19520.	0.8	0
208	Neuroendocrine differentiation in carcinoma of the prostate: An institutional review.. <i>Journal of Clinical Oncology</i> , 2014, 32, e16109-e16109.	0.8	0
209	Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary. <i>Clinical and Translational Oncology</i> , 2013, 15, 659-664.	1.2	3
210	Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey. <i>Clinical and Translational Oncology</i> , 2013, 15, 477-483.	1.2	12
211	Cancer-associated fibroblast and $\alpha$ 2 macrophage markers together predict outcome in colorectal cancer patients. <i>Cancer Science</i> , 2013, 104, 437-444.	1.7	235
212	Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report. <i>Respiratory Medicine Case Reports</i> , 2013, 9, 8-10.	0.2	13
213	Promising new molecule-targeted therapies and their integration into radiotherapy for lung cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, S18-S19.	0.3	0
214	Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. <i>Medical Oncology</i> , 2013, 30, 572.	1.2	21
215	False-positive interpretations in respiratory cytopathology. <i>Clinical Rheumatology</i> , 2013, 32, 15-17.	1.0	1
216	Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8002-LBA8002.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Interim analysis of The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small-cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC). <i>Journal of Clinical Oncology</i> , 2013, 31, LBA8002-LBA8002.	0.8	1
218	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943
219	Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. <i>Cancer Treatment Reviews</i> , 2012, 38, 36-53.	3.4	57
220	Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. <i>Lung Cancer</i> , 2012, 76, 354-361.	0.9	29
221	Surveillance of resected non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 721-725.	1.2	7
222	Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 883-890.	1.1	22
223	Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?. <i>Clinical and Translational Oncology</i> , 2012, 14, 386-390.	1.2	4
224	Breast cancer occurred after Hodgkin's disease: Clinico-pathological features, treatments and outcome: Analysis of 214 cases. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 29-37.	2.0	29
225	Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. <i>Investigational New Drugs</i> , 2012, 30, 729-740.	1.2	36
226	Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.. <i>Blood</i> , 2012, 120, 2672-2672.	0.6	1
227	Invasive ductal breast cancer, tumor size, and its correlation between physical examination, imaging techniques, and pathological anatomy.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11035-e11035.	0.8	0
228	Prognostic value of Bcl-2 in breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11527-e11527.	0.8	0
229	Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas. <i>Blood</i> , 2012, 120, 300-300.	0.6	0
230	Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel. <i>Actas Urológicas Españolas (English Edition)</i> , 2011, 35, 57-60.	0.2	0
231	Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. <i>Lung Cancer</i> , 2011, 71, 191-198.	0.9	45
232	Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1-14.	0.6	16
233	3529 POSTER Effect of Sample Type and Turnaround Time (TAT) on the Feasibility of Non-Small Cell Lung Cancer (NSCLC) Epidermal Growth Factor Receptor (EGFR) Mutation Testing in Routine Clinical Practice: Results From the Spanish REASON Study. <i>European Journal of Cancer</i> , 2011, 47, S255.	1.3	0
234	Epstein-Barr virus in the germinal centres of adenopathies affected by classic Hodgkin lymphoma. <i>Histopathology</i> , 2011, 59, 349-352.	1.6	5

#	ARTICLE	IF	CITATIONS
235	Activity of trabectedin in desmoplastic small round cell tumor. <i>Medical Oncology</i> , 2011, 28, 644-646.	1.2	21
236	Central nervous system involvement in Hodgkin's lymphoma. <i>Medical Oncology</i> , 2011, 28, 505-508.	1.2	10
237	PET-CT in the staging and treatment of non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 368-377.	1.2	16
238	Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). <i>Clinical and Translational Oncology</i> , 2011, 13, 411-418.	1.2	0
239	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 1160-1168.	3.2	292
240	Heterogeneous expression of Src tyrosine kinases Lyn, Fyn and Syk in classical Hodgkin lymphoma: prognostic implications. <i>Leukemia and Lymphoma</i> , 2011, 52, 2162-2168.	0.6	14
241	Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. <i>European Respiratory Journal</i> , 2011, 37, 617-623.	3.1	260
242	Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.. <i>Journal of Clinical Oncology</i> , 2011, 29, 7588-7588.	0.8	6
243	Inoperable stage III non-small cell lung cancer: Current treatment and role of vinorelbine. <i>Journal of Thoracic Disease</i> , 2011, 3, 197-204.	0.6	44
244	Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 384-386.	1.2	1
245	New Molecular Targeted Therapies Integrated With Radiation Therapy in Lung Cancer. <i>Clinical Lung Cancer</i> , 2010, 11, 91-97.	1.1	56
246	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. <i>European Journal of Haematology</i> , 2010, 85, 321-328.	1.1	49
247	Tumor Microenvironment and Immune Effects of Antineoplastic Therapy in Lymphoproliferative Syndromes. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-17.	3.0	13
248	Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 2021-2030.	0.6	8
249	Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. <i>Lung Cancer</i> , 2010, 68, 415-419.	0.9	8
250	Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2010, 68, 491-497.	0.9	13
251	Late relapses in Hodgkin lymphoma: a clinical and immunohistochemistry study. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-6.	0.6	15
252	Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment.. <i>Journal of Clinical Oncology</i> , 2010, 28, e18109-e18109.	0.8	1

#	ARTICLE	IF	CITATIONS
253	mRNA expression of protein phosphatase 2A/C (PP2A/C) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.. Journal of Clinical Oncology, 2010, 28, e18037-e18037.	0.8	0
254	Prevalence and management of anemia in patients with non-myeloid tumors undergoing systemic therapy.. Journal of Clinical Oncology, 2010, 28, e19658-e19658.	0.8	0
255	A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 1642-1646.	0.6	8
256	Differential Genetic and Functional Markers of Second Neoplasias in Hodgkin's Disease Patients. Clinical Cancer Research, 2009, 15, 4823-4828.	3.2	12
257	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology, 2009, 11, 284-289.	1.2	14
258	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clinical and Translational Oncology, 2009, 11, 428-436.	1.2	4
259	Lung cancer and treatment in elderly patients: The Achilles Study. Lung Cancer, 2009, 66, 103-106.	0.9	18
260	Cancer Treatments: Can We Find Treasures at the Bottom of the Sea?. Clinical Lung Cancer, 2009, 10, 295-300.	1.1	23
261	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. New England Journal of Medicine, 2009, 361, 958-967.	13.9	2,213
262	Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. PLoS ONE, 2009, 4, e5133.	1.1	153
263	Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival Implications. PLoS ONE, 2009, 4, e8173.	1.1	26
264	Hodgkin's disease and intercurrent processes that may simulate a relapse. Clinical and Translational Oncology, 2008, 10, 439-441.	1.2	1
265	R-CHOP-14 in patients with diffuse large B-cell lymphoma younger than 70 years: a multicentre, prospective study. Hematological Oncology, 2008, 26, 27-32.	0.8	15
266	A Phase II Study of Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. Clinical Breast Cancer, 2008, 8, 149-154.	1.1	34
267	Analysis of Competing Risks of Causes of Death and their Variation Over Different Time Periods in Hodgkin's Disease. Clinical Cancer Research, 2008, 14, 5300-5305.	3.2	11
268	Flumazenil in the Treatment of Dizziness and Vegetative Symptoms after Intravenous Infusion of Paclitaxel. Onkologie, 2008, 31, 203-203.	1.1	1
269	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research, 2008, 14, 4794-4799.	3.2	99
270	Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer: Final Results of an International Phase II Trial. Journal of Thoracic Oncology, 2008, 3, 994-1002.	0.5	48

#	ARTICLE	IF	CITATIONS
271	Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 2747-2754.	0.8	445
272	Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non-Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. <i>Journal of Clinical Oncology</i> , 2007, 25, 4736-4742.	0.8	104
273	Excision repair cross complementing 6 (ERCC6) single nucleotide polymorphism (SNP) and outcome to gemcitabine (gem)/cisplatin (cis) or docetaxel (doc)/cis in stage IV non-small cell lung cancer (NSCLC) patients (pts). <i>Journal of Clinical Oncology</i> , 2007, 25, 7605-7605.	0.8	0
274	Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. <i>Blood</i> , 2006, 108, 662-668.	0.6	131
275	Extracellular tumor DNA in plasma and overall survival in breast cancer patients. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 692-701.	1.5	41
276	Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. <i>Annals of Oncology</i> , 2006, 17, 467-472.	0.6	117
277	Implication of Polycomb Members Bmi-1, Mel-18, and Hpc-2 in the Regulation of p16INK4a, p14ARF, h-TERT, and c-Myc Expression in Primary Breast Carcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 6929-6936.	3.2	76
278	Rapid-infusion rituximab in lymphoma treatment. <i>Annals of Oncology</i> , 2006, 17, 1027-1028.	0.6	25
279	Association Between Hepatitis C Virus and Non-Hodgkin's Lymphomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 3513-3513.	0.8	2
280	Thymidylate Synthase Messenger RNA Expression in Plasma from Patients with Colon Cancer: Prognostic Potential. <i>Clinical Cancer Research</i> , 2006, 12, 2095-2100.	3.2	35
281	Gemcitabine in Multi-Resistant Non-Hodgkin Lymphomas. <i>Tumori</i> , 2004, 90, 363-364.	0.6	0
282	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 1318-1325.	3.2	345
283	Overexpression of p16INK4a correlates with high expression of p73 in breast carcinomas. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2004, 554, 215-221.	0.4	13
284	Intronic deletion affecting a negative regulatory region of TP73 is related to breast and colorectal carcinomas. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 257-262.	1.5	7
285	Promoter methylation of the PTEN gene is a common molecular change in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 117-124.	1.5	196
286	Prognostic Factors in Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 2004, 45, 1133-1139.	0.6	12
287	Cancer Antigen 125 Associated With Multiple Benign and Malignant Pathologies. <i>Annals of Surgical Oncology</i> , 2003, 10, 150-154.	0.7	129
288	Targeted therapy in combination with gemcitabine in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2003, 30, 19-25.	0.8	34

#	ARTICLE	IF	CITATIONS
289	Concomitant expression of p16INK4a and p14ARF in primary breast cancer and analysis of inactivation mechanisms. <i>Journal of Pathology</i> , 2003, 199, 289-297.	2.1	100
290	Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 20-27.	0.8	420
291	Intratumoral Heterogeneity in Microsatellite Alterations in BRCA1 and PTEN Regions in Sporadic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2003, 10, 876-881.	0.7	13
292	The Management of Stage III Supradiaphragmatic Hodgkin's Disease with Chemotherapy Alone. <i>Leukemia and Lymphoma</i> , 2003, 44, 263-268.	0.6	4
293	Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer. <i>Gut</i> , 2003, 52, 1756-1763.	6.1	26
294	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 3207-3213.	0.8	177
295	The topoisomerase II $\alpha$ expression correlates with survival in patients with advanced Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2003, 9, 1406-11.	3.2	12
296	Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. <i>Gut</i> , 2002, 50, 530-534.	6.1	124
297	Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. <i>Annals of Surgical Oncology</i> , 2002, 9, 71-76.	0.7	61
298	Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. <i>Clinical Cancer Research</i> , 2002, 8, 3761-6.	3.2	97
299	Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. <i>Radiotherapy and Oncology</i> , 2001, 59, 247-255.	0.3	92
300	Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2001, 66, 183-190.	1.1	52
301	Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. <i>Oncogene</i> , 2001, 20, 4586-4590.	2.6	46
302	Hodgkin's Disease: Unsuspected Minimal Activity in Patients that Die from Causes Other than Tumoral Progression. <i>Leukemia and Lymphoma</i> , 2001, 42, 661-664.	0.6	4
303	Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. <i>Clinical Cancer Research</i> , 2001, 7, 2821-5.	3.2	105
304	Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance. <i>Annals of Oncology</i> , 2000, 11, 1097-1104.	0.6	81
305	Hodgkin's disease: Correlation between causes of death at autopsy and clinical diagnosis. <i>Annals of Oncology</i> , 2000, 11, 59-64.	0.6	16
306	Absence of point mutations at codon 17 of the Mdm2 gene (serine 17) in human primary tumors. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2000, 449, 41-45.	0.4	6

#	ARTICLE	IF	CITATIONS
307	DNA damage after chemotherapy correlates with tumor response and survival in small cell lung cancer patients. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2000, 456, 65-71.	0.4	5
308	Clinicopathological characteristics of breast carcinomas with allelic loss in the p73. <i>Breast Cancer Research and Treatment</i> , 2000, 63, 17-22.	1.1	8
309	Mutational status of K-ras and TP53 genes in primary sarcomas of the heart. <i>British Journal of Cancer</i> , 2000, 82, 1183-1185.	2.9	40
310	Metastatic Renal Cell Carcinoma to the Head and Neck Area. <i>Tumori</i> , 2000, 86, 88-90.	0.6	17
311	Testicular Germ Cell Tumor and down Syndrome. <i>Tumori</i> , 2000, 86, 431-433.	0.6	4
312	Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. <i>British Journal of Cancer</i> , 1999, 80, 1262-1264.	2.9	116
313	Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations. <i>British Journal of Cancer</i> , 1999, 81, 503-509.	2.9	70
314	Loss of heterozygosity in BRCA1 and BRCA2 markers and high grade malignancy in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999, 53, 9-17.	1.1	31
315	Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. <i>Breast Cancer Research and Treatment</i> , 1999, 57, 237-243.	1.1	104
316	Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, S5-S8.	1.1	3
317	Comparison of the long-term mortality in Hodgkin's disease patients with that of the general population. <i>Annals of Oncology</i> , 1999, 10, 1199-1205.	0.6	7
318	Low Incidence of Germline BRCA2 Gene Mutations among Spanish Breast Cancer Patients. <i>Oncology</i> , 1999, 57, 173-174.	0.9	4
319	Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. <i>Cancer Research</i> , 1999, 59, 3251-6.	0.4	169
320	Loss of Heterozygosity in the Region Including the BRCA1 Gene on 17q in Colon Cancer. <i>Cancer Genetics and Cytogenetics</i> , 1998, 104, 119-123.	1.0	36
321	BRCA1 Mutations in Patients with Familial Risk of Breast Cancer. <i>Acta Oncológica</i> , 1998, 37, 299-300.	0.8	0
322	Detection of BRCA1 gene mutations in families with breast cancer patients and their healthy relatives. <i>International Journal of Oncology</i> , 1998, 13, 275-9.	1.4	1
323	Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations. <i>Journal of Clinical Oncology</i> , 1998, 16, 115-120.	0.8	34
324	Prognostic implications of loss of heterozygosity in the 17q21 region in breast cancer. <i>International Journal of Oncology</i> , 1997, 10, 659-63.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Presence of germline BRCA2 mutations in sporadic breast cancer: Clinical correlation. <i>European Journal of Cancer</i> , 1997, 33, S11.	1.3	0
326	Breast Angiosarcoma After Radiation Therapy. <i>Acta Oncol</i> 3gica, 1995, 34, 969-969.	0.8	23
327	Primary osteosarcoma of the meninges. <i>Annals of Oncology</i> , 1994, 5, 965-966.	0.6	12
328	Malignant Fibrous Histiocytoma of the Spleen and Chronic Myelogenous Leukemia. <i>Oncology</i> , 1994, 51, 465-466.	0.9	13
329	Cerebral infarction after cisplatin-based chemotherapy.. <i>Postgraduate Medical Journal</i> , 1994, 70, 525-526.	0.9	5
330	Multiple Primary Tumors and Familial Cancers. A Case Report. <i>Tumori</i> , 1993, 79, 273-274.	0.6	0
331	Pneumomediastinum after belching. <i>Lancet, The</i> , 1990, 336, 1390.	6.3	3
332	Sympathetic nervous system mediates central corticotropin-releasing factor induced suppression of natural killer cytotoxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1990, 255, 101-7.	1.3	77
333	mTOR inhibitor in the treatment of Hodgkin&rsquo;s lymphoma: a case report. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, , 19.	1.2	1